

## Special Issue

# Target and Im-Oncology Therapeutic Approaches for Lung Cancer

### Message from the Guest Editors

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1.8 million people are diagnosed with lung cancer, and 1.6 million people die as a result of the disease. Five-year survival rates vary from 4 to 17% depending on stage and regional differences. Recognition that lung cancer is primarily a disease of the genome has fueled recent focus on the development of more personalized or precision treatments based on genomic information. Lung cancer can thus be subdivided into clinically relevant molecular subsets, including EGFR, ALK, ROS1, HER2, BRAF, KRAS, RET, MET, and so on. Targeted therapy could lead to substantial outcome improvements. Meanwhile, unprecedented advances have been made in lung cancer treatment with the use of immunotherapy. However, limited responses to a subset of patients, drug resistance, and treatment-related adverse events are still unsolved. The scope of this Special Issue is to provide an overview of recent advances in the field of targeted therapy and immunotherapy for lung cancer. Therefore, researchers in this field are encouraged to submit an original article or review to this Special Issue.

### Guest Editors

Prof. Dr. Shun Lu

Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China

Prof. Dr. Yongfeng Yu

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China

### Deadline for manuscript submissions

closed (25 April 2023)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/110689](https://mdpi.com/si/110689)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1  
(General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).